Roivant Sciences (ROIV) Expected to Announce Earnings on Friday

Roivant Sciences (NASDAQ:ROIV) will likely be releasing its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect Roivant Sciences to post earnings of ($0.27) per share and revenue of $6.1390 million for the quarter. Parties may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, February 6, 2026 at 8:00 AM ET.

Roivant Sciences Stock Performance

ROIV stock opened at $22.02 on Friday. The firm has a 50 day simple moving average of $21.87 and a 200 day simple moving average of $17.32. Roivant Sciences has a 52 week low of $8.73 and a 52 week high of $23.91. The stock has a market cap of $15.31 billion, a P/E ratio of -39.32 and a beta of 1.22.

Insider Transactions at Roivant Sciences

In related news, insider Mayukh Sukhatme sold 1,018,995 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $21.71, for a total value of $22,122,381.45. Following the sale, the insider owned 20,267,429 shares of the company’s stock, valued at $440,005,883.59. The trade was a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Daniel Allen Gold sold 777,332 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $23.07, for a total value of $17,933,049.24. Following the completion of the sale, the director owned 16,353,113 shares in the company, valued at approximately $377,266,316.91. This represents a 4.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 12,332,392 shares of company stock worth $266,393,645. 10.80% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

Several large investors have recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Utah Retirement Systems increased its position in shares of Roivant Sciences by 3.0% in the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after buying an additional 600 shares in the last quarter. M&T Bank Corp raised its stake in Roivant Sciences by 10.2% during the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares during the period. Crossmark Global Holdings Inc. raised its stake in Roivant Sciences by 7.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 22,765 shares of the company’s stock worth $344,000 after buying an additional 1,572 shares during the period. Finally, American Century Companies Inc. lifted its holdings in Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after acquiring an additional 1,689 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on ROIV. Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Roivant Sciences in a research note on Thursday, January 22nd. HC Wainwright increased their target price on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, The Goldman Sachs Group raised their target price on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.